Members |
targetComponentId |
Over the counter nicotine replacement therapy |
Nicotine replacement therapy |
överdos av natriumvalproat |
Valproate overdose |
överdos av natriumvalproat, med oklar avsikt |
Valproate overdose |
tröstätande förenat med andra psykiska störningar |
Psychogenic overeating |
Overexposure to radioactive isotope NOS |
Overexposure to radioactive isotopes |
hypergranulerande operationssår under sekundär sårläkning |
Over-granulating secondary intention surgical wound (finding) |
övergripande malign tumör på oklart ställe |
Malignant neoplastic disease (disorder) |
mer än 11 timmars nattfasta |
Overnight fasting period more than 11 hours |
överridande höger ventrikuloarteriell klaff |
Pulmonary valve overriding ventricular septum (disorder) |
Ovis musimon |
Ovis aries |
ovotestis |
Ovotesticular disorder of sex development |
Ovula Nabothi |
Retention cyst |
oxacillinnatrium 250 mg/5 ml, pulver till oral lösning |
Product containing precisely oxacillin 50 milligram/1 milliliter conventional release oral suspension (clinical drug) |
poäng enligt Oxford knee score, version 1.0 |
Oxford Knee Score using revised scoring system (observable entity) |
Oxidase |
Oxidase |
Oxo-acid-lyase |
Oxo-acid-lyase |
Oxybuprocaine 0.4% eye drops |
Oxybuprocaine only product |
oxibuprokainhydroklorid 0,4 %, ögondroppar |
Oxybuprocaine only product |
oxibuprokainhydroklorid 0,4 %, ögondroppar för engångsbruk |
Oxybuprocaine only product |
oxibutynin 3,9 mg/dag, transdermalt system |
Product containing precisely oxybutynin 162 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
oxibutyninhydroklorid 15 mg, tablett med modifierad frisättning |
Oxybutynin only product in oral dose form |
oxibutyninhydroklorid 15 mg, depåtablett |
Oxybutynin only product in oral dose form |
oxikodonhydroklorid 160 mg, tablett med modifierad frisättning |
Product containing only oxycodone in oral dose form (medicinal product form) |
oxikodonhydroklorid 160 mg, depåtablett |
Product containing only oxycodone in oral dose form (medicinal product form) |
Oxygenase |
Oxygenase |
oximetazolinhydroklorid 0,025 %, näsdroppar |
Oxymetazoline hydrochloride 250 microgram/mL nasal solution |
oximetazolinhydroklorid 0,05 %, ögondroppar |
Oxymetazoline hydrochloride 500 microgram/mL eye solution |
oximetazolinhydroklorid 0,05 %, näsdroppar |
Oxymetazoline hydrochloride 500 microgram/mL nasal solution |
oximorfon 10 mg, tablett med modifierad frisättning |
Oxymorphone only product in oral dose form |
oximorfon 10 mg, depåtablett |
Oxymorphone only product in oral dose form |
oximorfon 20 mg, tablett med modifierad frisättning |
Oxymorphone only product in oral dose form |
oximorfon 20 mg, depåtablett |
Oxymorphone only product in oral dose form |
oximorfon 40 mg, tablett med modifierad frisättning |
Oxymorphone only product in oral dose form |
oximorfon 40 mg, depåtablett |
Oxymorphone only product in oral dose form |
oximorfon 5 mg, tablett med modifierad frisättning |
Oxymorphone only product in oral dose form |
oximorfon 5 mg, depåtablett |
Oxymorphone only product in oral dose form |
Oxytocic preparation |
Medicinal product acting as oxytocic (product) |
oxytocin 10 enheter/ml, infusionsvätska, lösning, flaska 1 ml |
Product containing precisely oxytocin 10 unit/1 milliliter conventional release solution for injection (clinical drug) |
ostron, livsmedel |
Oyster (substance) |
PegIntron, Redipen |
Product containing peginterferon alfa-2b (medicinal product) |
PegIntron 120 mikrogram pulver + sterilt vatten 0,5 ml, Redipen |
Interferon alfa-2b (as peginterferon alfa-2b) 120 microgram powder for solution for injection pen |
PegIntron 150 mikrogram pulver + sterilt vatten 0,5 ml, Redipen |
Interferon alfa-2b (as peginterferon alfa-2b) 150 microgram powder for solution for injection pen |
PegIntron 50 mikrogram pulver + sterilt vatten 0,5 ml, Redipen |
Interferon alfa-2b (as peginterferon alfa-2b) 50 microgram powder for solution for injection pen |
PegIntron 80 mikrogram pulver + sterilt vatten 0,5 ml, Redipen |
Interferon alfa-2b (as peginterferon alfa-2b) 80 microgram powder for solution for injection pen |
PIE syndrome |
Löffler's syndrome (disorder) |
Packing - action |
Insertion - action (qualifier value) |
läkemedelseluerande stent innehållande paclitaxel 1 mikrogram/mm |
Paclitaxel 1 microgram/mm2 drug eluting stent (product) |
Painful ejaculation |
Painful ejaculation |
lambå från hårda gommen |
Flap (substance) |
Palatoplasty |
Uvulopalatopharyngoplasty |
Pale faeces |
Pale feces |
Pale faeces |
Pale feces |
ljus avföring, symtom |
Pale feces |
blekröd färg |
Pale red colour |
pamidronatdinatrium 3 mg/ml, infusionskoncentrat, flaska 5 ml |
Product containing precisely disodium pamidronate 3 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Pancreas excision |
Pancreatectomy |
pankrelipas, amylas:lipas, kapsel à 183,49 g |
Amylase and pancrelipase and triacylglycerol lipase only product |
pankrelipas, amylas:lipas, kapsel à 184,84 mg |
Amylase and pancrelipase and triacylglycerol lipase only product |
pankrelipas, amylas:lipas, kapsel à 210,33 mg |
Amylase and pancrelipase and triacylglycerol lipase only product |
pankrelipas, amylas:lipas, 278,72 %, kapsel |
Amylase and pancrelipase and triacylglycerol lipase only product |
pankrelipas, amylas:lipas, kapsel à 312,17 mg |
Amylase and pancrelipase and triacylglycerol lipase only product |
pankrelipas, amylas:lipas, kapsel à 346,86 mg |
Amylase and pancrelipase and triacylglycerol lipase only product |
pankrelipas, amylas:lipas, 4 500 enheter, kapsel |
Amylase and pancrelipase and triacylglycerol lipase only product |
pankrelipas, amylas:lipas, 62,81 % |
Amylase and pancrelipase and triacylglycerol lipase only product |
pankrelipas, amylas:lipas, 62,81 %, kapsel |
Amylase and pancrelipase and triacylglycerol lipase only product |
pankrelipas, amylas:lipas, kapsel à 94,3 mg |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pantoprazole sodium 40mg injection |
Pantoprazole (as pantoprazole sodium) 40 mg powder for solution for injection vial |
Pantoprazole sodium 40mg m/r tablet |
Pantoprazole (as pantoprazole sodium) 40 mg gastro-resistant oral tablet |
Pantoprazole sodium 40mg powder |
Pantoprazole (as pantoprazole sodium) 40 mg powder for solution for injection vial |
Pantoprazole sodium 40mg/vial powder for injection |
Pantoprazole (as pantoprazole sodium) 40 mg powder for solution for injection vial |
papainspecifikt extrakt |
Product containing papain (medicinal product) |
papaya, livsmedel |
Papaya (substance) |
Paphosia adorabilis |
Lophornis adorabilis (organism) |
Papillary cystadenoma, borderline malignancy |
Papillary cystadenoma, borderline malignancy |
Papillary mucinous cystadenoma, borderline malignancy |
Papillary mucinous cystadenoma, borderline malignancy |
papillärt seröst cystadenokarcinom |
Serous cystadenocarcinoma |
Papillary serous cystadenoma, borderline malignancy |
Serous papillary cystic tumour of borderline malignancy |
papillom (förutom papillom i blåsa M-81201) |
Benign papilloma (morphologic abnormality) |
antiinflammatoriskt medel med para-aminofenolderivat |
Para-aminophenol derivative |
paracetamol 500 mg + klorfenaminmaleat 8 mg + fenylefrinhydroklorid 40 mg |
Product containing only chlorphenamine and paracetamol and phenylephrine (medicinal product) |
paracetamol 500 mg + orfenadrincitrat 50 mg |
Orphenadrine and paracetamol only product |
Paracetamol - chemical |
Product containing paracetamol (medicinal product) |
Paracetamol 1g/sachet powder |
Paracetamol only product |
Paracetamol 1g/sachet powder |
Paracetamol only product |
paracetamol 500 mg, löslig tablett |
Product containing precisely paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
paracetamol 650 mg + pentazocinhydroklorid 25 mg, kapseltablett |
Paracetamol 650 mg and pentazocine 25 mg oral tablet |
paracetamol 650 mg + pentazocinhydroklorid 25 mg, tablett |
Paracetamol 650 mg and pentazocine 25 mg oral tablet |
Paracetamol level abnormal |
Acetaminophen above therapeutic range |
Paracetamol level normal |
Acetaminophen within therapeutic range |
paracetamol 500 mg + koffein 65 mg, löslig tablett |
Product containing precisely caffeine 650 microgram/1 milliliter and paracetamol 5 milligram/1 milliliter conventional release oral solution (clinical drug) |
Parafunctional occlusal trauma |
Secondary occlusal trauma |
Parahyaena brunnea |
Hyaena brunnea (organism) |
Paramyxovirus |
Genus Respirovirus (organism) |
Paramyxovirus group |
Genus Respirovirus (organism) |
syndrom med paraplegi, brakydaktyli och konformad epifys |
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (disorder) |
fasciokutan paraskapulär lambå |
Fasciocutaneous flap |
fasciokutan paraskapulär lambå samt scapula |
Osteofasciocutaneous flap (substance) |
parasomni orsakad av substans |
Parasomnia |
Parathormone |
Parathyroid hormone |
parecoxib 40 mg, pulver för beredning av injektionsvätska |
Parecoxib only product |
parecoxib 40 mg, pulver för beredning av injektionsvätska + spädningsvätska |
Parecoxib only product |